Stocks · Healthcare · Biotechnology
RenovoRx, Inc. RNXT
$1.58 +1.94% Close, Oct 2, 2026 · NASDAQ · Market cap $71.2M
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Revenue over the last four quarters was $2.0M, up 198.5% from a year earlier, slowing from 520.4% a quarter earlier.
- Operating margin widened to -678.0% from -1699.1% a year earlier.
- The diluted share count rose 29.3% in a year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 6%
- Revenue growth accelerationBottom 2%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 5%
- Gross marginTop 26%
- Operating marginBottom 14%
- Accruals (lower is better)Bottom 32%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 33%
- Free-cash-flow yieldBottom 27%
- EBITDA / enterprise valueBottom 28%
- Sales / enterprise valueBottom 16%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 21%
- 6-month returnTop 16%
- 1-year return vs S&P 500Top 45%
- Distance from 52-week highBottom 41%
- Trend checklist (0–4)Top 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 42%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyTop 45%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 7%
- Maximum drawdown, 3 yearsTop 47%
- Beta vs S&P 500 (lower is better)Top 35%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 520.4% | 198.5% | ↓ |
| Gross margin | 62.8% | 84.4% | ↑ |
| Operating margin | -1699.1% | -678.0% | ↑ |
| FCF margin | -1559.1% | -604.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 198.5% | 520.4% | ↓ | Top 6% |
| Gross margin | 84.4% | 62.8% | ↑ | Top 26% |
| Operating margin | -678.0% | -1699.1% | ↑ | Bottom 14% |
| Net margin | -621.7% | -1610.9% | ↑ | — |
| Free-cash-flow margin | -604.1% | -1559.1% | ↑ | — |
| Return on invested capital | -139.7% | — | Bottom 5% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -3.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 77.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- -166.3 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -14.53%
- Shareholder yield
- -14.53%
- Share count change, 1 year
- +29.3%
- Share count change, 3-year CAGR
- +30.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 13, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- +7.8%
- Average 2-day reaction, last 8
- -0.5%
- Positive 20 days after report
- 5 of 8
Analysts
- Analysts with a rating
- 5
- Share rating Buy or Strong Buy
- 80%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 12, 2026 | +31.0% | -2.6% | +1.7% | +73.9% | — |
| May 14, 2026 | +0.0% | +0.8% | -4.5% | +1.9% | +36.7% |
| Mar 30, 2026 | +0.0% | -5.3% | -17.5% | -23.0% | -15.7% |
| Nov 13, 2025 | +0.0% | -2.6% | -26.7% | -0.7% | -1.0% |
| Aug 14, 2025 | +0.0% | +1.6% | -28.7% | +1.6% | -20.8% |
| May 15, 2025 | +0.0% | +5.7% | +16.2% | +29.5% | +6.7% |
| Mar 31, 2025 | +7.7% | -1.0% | -11.9% | -2.8% | +38.0% |
| Nov 13, 2024 | +16.7% | -0.9% | +0.9% | +28.2% | +4.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.05 | -$0.07 | +31.0% | $909,000 |
| May 14, 2026 | -$0.08 | -$0.08 | +0.0% | $563,000 |
| Mar 30, 2026 | -$0.08 | -$0.08 | +0.0% | $238,000 |
| Nov 13, 2025 | -$0.08 | -$0.08 | +0.0% | $266,000 |
| Aug 14, 2025 | -$0.08 | -$0.08 | +0.0% | $422,000 |
| May 15, 2025 | -$0.08 | -$0.08 | +0.0% | $197,000 |
| Mar 31, 2025 | -$0.12 | -$0.13 | +7.7% | $43,000 |
| Nov 13, 2024 | -$0.10 | -$0.12 | +16.7% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 31.36× | — | — | Bottom 16% |
| Free-cash-flow yield | -16.77% | — | — | Bottom 27% |
| Earnings yield | -20.02% | — | — | Bottom 33% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 46
- Days above the 200-day average
- 45
- 50-day average slope (20 days)
- +28.5%
- 200-day average slope (20 days)
- +8.7%
- Distance from 50-day average
- +6.4%
- Distance from 200-day average
- +47.9%
- RSI (14)
- 47.4
- Relative volume
- 0.27×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 107.5%
- Volatility vs own 5-year history
- 76th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.87
- Correlation with S&P 500
- 0.16
- Current drawdown from 1-year high
- -37.3%
- Maximum drawdown, 3 years
- -68.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Aug 30, 2021 | Nov 17, 2023 | -96.3% | 559 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $71.2M
- EPS, diluted (TTM)
- -$0.32
- Revenue (TTM)
- $2.0M
- 52-week range
- $0.70 – $2.59
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $43,000 | $1.1M |
| Gross profit | $0 | $0 | $0 | $43,000 | $796,000 |
| Operating income | -$5.7M | -$9.9M | -$11.4M | -$11.0M | -$12.5M |
| Net income | -$6.3M | -$9.9M | -$10.2M | -$8.8M | -$11.2M |
| EPS (diluted) | -$0.40 | -$0.54 | -$0.50 | -$0.37 | -$0.32 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $43,000 | $197,000 | $422,000 | $266,000 | $238,000 | $563,000 | $909,000 |
| Net income | -$2.5M | -$2.9M | -$2.4M | -$2.9M | -$2.9M | -$2.9M | -$3.5M | -$2.9M |
| EPS (diluted) | -$0.10 | -$0.13 | -$0.08 | -$0.08 | -$0.08 | -$0.08 | -$0.09 | -$0.06 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M |
| Capital expenditure | -$15,000 | $0 | $0 | -$12,000 | -$2,000 |
| Free cash flow | -$5.9M | -$8.8M | -$10.3M | -$9.1M | -$11.0M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $14.6M | $42,000 | $5.0M | $15.0M | $12.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $9.5M
- Total assets
- $11.5M
- Total liabilities
- $2.5M
- Total debt
- $259,000
- Net debt
- -$9.2M
- Shareholders’ equity
- $9.0M
As of Jun 30, 2026 (filed Aug 13, 2026).
Short interest
- Shares sold short
- 673,558
- Days to cover
- 1.00
- Change vs previous report
- +55.6%
FINRA short interest, settlement date Sep 15, 2026.